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Results from the BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) Trial
Objectives The purpose of this analysis was to assess in patients with type 2 diabetes and stable coronary artery disease
(CAD) whether the risk of all-cause mortality and cardiovascular events varied according to the presence or ab-
sence of angina and angina equivalent symptoms.
Background Data on the prognostic value of symptoms in these patients are limited.
Methods Post-hoc analysis was performed in 2,364 patients with type 2 diabetes and documented CAD enrolled in the
BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial to determine the occurrence of
death and composite of death, myocardial infarction, and stroke during a 5-year follow-up according to cardiac
symptoms at baseline.
Results There were 1,434 patients with angina (A), 506 with angina equivalents (E), and 424 with neither of these (N).
The cumulative death rates (total 316) were 12% in A, 14% in E, and 10% in N (p  0.3), and cardiovascular
composite rates (total 548) were 24% in A, 24% in E, and 21% in N (p  0.5). Compared with N, the hazard ra-
tios adjusted for confounders were not different for death in A (1.11; 99% CI: 0.81 to 1.53) and E (1.17; 99% CI:
0.81 to 1.68) or for cardiovascular events in A (1.17; 99% CI: 0.92 to 1.50) and E (1.11; 99% CI: 0.84 to 1.48).
Conclusions Whatever their symptom status, patients with type 2 diabetes and stable CAD were at similar risk of cardiovascular
events and death. These findings suggest that these patients may be similarly managed in terms of risk stratification
and preventive therapies. (Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D];
NCT00006305) (J Am Coll Cardiol 2013;61:702–11) © 2013 by the American College of Cardiology FoundationPatients with type 2 diabetes and stable coronary artery
disease (CAD) may present with typical angina, angina
equivalents such as effort dyspnea, or no cardiac symptoms.
Such diversity raises the question whether symptom status
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2012, accepted November 8, 2012.affects prognosis in these patients. Silent ischemia may be
the first manifestation of ischemic heart disease and may
occur following coronary revascularization in previously
symptomatic patients. Exertional dyspnea as an angina equiv-
alent could be a manifestation of ischemia-induced systolic and/or
diastolic dysfunction and might signal severe coronary
disease portending a worse prognosis. On the other hand,
patients with typical angina might come to earlier medical
attention and treatment and have a better prognosis than
patients without “warning” symptoms. Prognostic studies of
patients with these clinical presentations are few, have
disparate findings, and are limited by small sample size, lack
of documentation of CAD, and short follow-up (1–3).
Given the limited and inconclusive evidence base and the need
to optimize risk stratification in patients with type 2 diabetes
and stable CAD, it is important to determine whether symp-
tom status impacts prognosis in these patients.
See page 712
The BARI 2D (Bypass Angioplasty Revascularization
Investigation 2 Diabetes) trial was carried out in 2,368
patients with type 2 diabetes and stable CAD with docu-
mented myocardial ischemia who were followed for 5.3
years. At entry into the study, BARI 2D patients had
angina, angina equivalents, or no cardiac symptoms (4).
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Prognosis of Symptoms in Diabetes With CAD February 19, 2013:702–11Data from this trial constitute an
important source of information
to assess the prognostic relevance
of symptom status in these pa-
tients. We thus tested the hy-
pothesis that BARI 2D patients
without angina or angina equiv-
alent symptoms at entry have a
risk of all-cause mortality and
cardiovascular events similar to
that of patients who have these
symptoms.
Methods
The BARI 2D trial was a random-
ized trial with a 2 2 factorial design to determine whether a
treatment strategy of prompt coronary revascularization and
optimal medical therapy was superior to a strategy of
initial optimal medical treatment alone with the option of
subsequent revascularization and whether a strategy using
insulin-sensitizing agents was more efficient than a strat-
egy using insulin-providing agents to reduce total mor-
tality and the composite of death, nonfatal myocardial
infarction (MI) and nonfatal stroke. Details of the BARI
2D trial have been published (4 – 6) and are briefly
outlined.
Study population. The 2,368 participants in the BARI 2D
trial were recruited between January 1, 2001, and March 31,
2005, at 49 clinical sites: 1,499 participants were from the
United States, 356 from Brazil, 353 from Canada, 85 from
Mexico, and 75 from Austria and the Czech Republic.
Participants had to be age 25 years and have type 2
iabetes, stable CAD (50% stenosis in a major epicardial
oronary artery), and myocardial ischemia defined as a
ositive electrocardiographic, myocardial perfusion scan or
chocardiographic test induced by exercise or pharmacolog-
cal agents or the presence of typical angina with coronary
tenosis 70%. Patients with unstable angina who became
table on medical therapy before entry into the study were
ncluded. All patients had to have suitable coronary anatomy
or randomization into either percutaneous coronary inter-
ention (PCI) strata or coronary artery bypass graft surgery
CABG) strata. The main exclusion criteria were a clinical
ndication for immediate revascularization, coronary revas-
ularization within the 12 months before randomization,
eft main coronary disease, class III or IV heart failure,
erum creatinine2.0 mg/dl (177 mol/l), and glycosylated
emoglobin (HbA1c) 13.0%. The protocol was approved
by each institution’s review board or ethics committee. All
participants provided written informed consent.
Classifications of patients by symptoms. The principal
investigator at each BARI 2D center had to classify the
cardiac symptoms according to a standardized questionnaire
into angina, angina equivalents, and no symptoms based on
Abbreviations
and Acronyms
BMI  body mass index
CABG  coronary artery
bypass graft surgery
CAD  coronary artery
disease
CVD  cardiovascular
disease
HbA1c  glycosylated
hemoglobin
MI  myocardial infarction
PCI  percutaneous
coronary interventionthe medical history and findings of the stress test. Angina twas characterized by ischemic chest pain occurring on
exertion or stress relieved by rest and/or nitroglycerine. The
participants with angina were also characterized according
to their Canadian Cardiovascular Society (CCS) grades of
angina (7) including stabilized unstable angina in grade IV
CCS angina. Angina equivalents had to be manifested by
dyspnea, fatigue, or diaphoresis on exertion evaluated by the
principal investigator as abnormal and attributable to myo-
cardial ischemia. Finally, participants without symptoms
were classified as asymptomatic. Patients with both angina
and angina equivalents were included in the angina group.
Among the 2,368 participants enrolled in the BARI 2D
study, there was satisfactory information on baseline angina
status in 2,364, and they constituted the sample of the
present study.
Treatment and follow-up. Patients randomized to the
prompt revascularization strategy had to have PCI or
CABG within 4 weeks of randomization. Optimal medical
therapy in both strategies consisted of lifestyle management
targeting smoking cessation, diet, weight loss, regular phys-
ical exercise, and pharmacological therapy to maintain
HbA1c 7.0%, low-density lipoprotein cholesterol 100
g/dl (2.6 mmol/l), and blood pressure 130/80 mm Hg.
articipants received individualized antiangina medications,
ncluding beta-blockers, calcium channel blockers, and
ong-acting nitrates. If during the study patients developed
ncapacitating angina or angina equivalent symptoms, if
atients had documented worsening ischemia despite
ptimal medical treatment, or if an acute coronary syndrome
ccurred, the treating cardiologist could recommend
ubsequent coronary revascularization, which was defined
n the present analysis as the first revascularization
rocedure for patients randomized to optimal medical
trategy or the repeated revascularization procedure for
atients randomized to prompt revascularization strategy.
articipants were evaluated on a monthly basis for 6
onths and every 3 months thereafter for a mean
ollow-up of 5.3 years.
utcomes. The outcomes were all-cause death and the
omposite of all-cause death, nonfatal MI, and nonfatal
troke and have been previously described (4). Events were
djudicated by an independent committee unaware of the
tudy group allocation. Cardiac death included sudden
eath, fatal MI, congestive heart failure death, death within
0 days of a cardiac procedure, cardiogenic shock, unwit-
essed death, and presumed cardiac death. The clinical
iagnosis of nonprocedural MI was based on cardiac mark-
rs, either troponin or creatine kinase MB, with evidence of
schemia on the basis of symptoms, electrocardiography, or
maging. Stroke was defined as a rapid neurological deficit
ttributed to an obstruction or rupture of cerebral artery
asting 24 h or 24 h if there was a lesion on computer-
zed tomography or magnetic resonance imaging compatible
ith an acute stroke.
tatistical analysis. Major comparisons were made amonghe 3 groups based on baseline symptom status. Analysis of
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February 19, 2013:702–11 Prognosis of Symptoms in Diabetes With CADvariance was used for comparison of continuous variables
and chi-square test for categorical variables. If the
3-group comparison was statistically significant, then
post hoc pair-wise comparisons between each pair of
symptom status were performed to demonstrate which
pair differed significantly. The pairwise comparisons used
the Tukey-Kramer test for continuous variables and the
Wald test for categorical variables. Furthermore, com-
parisons among the severity degree (CCS grades) of
Baseline Characteristics by Baseline Angina StaTable 1 Baseline Characteristics by Baselin
Baseline Characteristics
Non
(n  4
Age, yrs 63.4
Male 78.
Smoking status
Never smoked 35.
Former smoker 53.
Current smoker 11.
History of hypertension 74.
Duration of diabetes, yrs 8.0 (3.5
Glycosylated hemoglobin 7.6
Total cholesterol, mg/dl 162 (141
LDL cholesterol, mg/dl 91 (75–
HDL cholesterol, mg/dl 37 (32–
Triglycerides, mg/dl 141 (97–
Body mass index, kg/m2 30.7
Michigan neuropathy score 2.4
History of myocardial infarction 32.
History of stroke 7.
Microalbuminuria 22.
Macroalbuminuria 9.
Estimated GFR, ml/min/1.73 m2 74.1 (62.
Peripheral artery disease 18.
Number of coronary vessel disease
1 27.
2 40.
3 31.
Myocardial jeopardy index score 47.4
Previous PCI 13.
Previous CABG surgery 4.
Left ventricular ejection fraction, % 56.9
Systolic blood pressure, mm Hg 131
Diastolic blood pressure, mm Hg 75
Antiplatelets* 15.
Aspirin 88.
Long-acting nitrates 16.
Statins 73.
Beta-blockers 67.
Calcium-channel blockers 29.
ACE inhibitors or ARBs 76.
Diuretics 34.
Glucose-lowering agents† 92.
Prompt revascularization‡ 32.
Values are mean  SD, %, or median (interquartile range). *Antipla
sulfinpyrazone. †Glucose-lowering agents included biguanide, thiaz
glucosidase inhibitor. ‡Coronary revascularization per protocol within 4
prompt revascularization arm.ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocke
rate; HDL  high-density lipoprotein; IQR  interquartile range; LDL  low-debaseline angina were also conducted for all outcomes.
Paralleling the aggregate analysis on all BARI 2D pa-
tients, the stratified analyses were performed on the 2
subgroups stratified by the randomization strategy (i.e.,
the prompt revascularization strategy vs. the optimal
medical strategy) to address the possible confounding
effect of the initial revascularization procedures on one-
half of the BARI 2D patients within 4 weeks of enroll-
ment. The cumulative incidence rate of outcomes was
gina Status
Equivalent
(n  506)
Angina
(n  1,434)
p Value
Among 3 Groups
63.5 8.9 61.7 8.9 0.0001
71.3 67.5 0.0001
0.7
31.5 32.9
55.4 54.4
13.1 12.7
84.8 84.1 0.0001
9.6 (4.2–16.1) 8.0 (3.6–15.2) 0.08
7.7 1.7 7.7 1.6 0.4
167 (142–190) 164 (141–194) 0.4
95 (74–117) 91 (72–114) 0.5
36 (31–43) 37 (31–43) 0.7
143 (102–215) 154 (108–224) 0.2
32.7 6.2 31.7 6.0 0.0001
2.5 1.7 2.4 1.7 0.4
30.6 32.5 0.7
9.7 10.4 0.2
26.0 21.9 0.2
12.0 8.9 0.1
) 76.1 (60.2–91.2) 76.7 (63.6–91.6) 0.5
25.9 24.5 0.03
0.03
37.6 33.5
33.3 35.4
29.1 31.1
41.6 25.0 44.6 23.8 0.001
17.4 22.1 0.0003
6.9 7.0 0.08
55.0 12.0 58.0 10.3 0.001
132 20 131 20 0.08
74 12 75 11 0.2
17.8 21.3 0.01
85.9 88.6 0.3
21.4 39.4 0.0001
74.8 75.6 0.6
66.5 76.7 0.0001
31.5 32.0 0.6
79.0 76.6 0.5
45.7 37.3 0.0005
93.7 90.2 0.04
38.2 39.8 0.03
ncluded ticlopidine, clopidogrel, and others such as dipyridamole or
ione, sulfonylurea, meglitinide, phenylalanine derivative, or alpha
of randomization, either PCI or CABG among patients randomized totuse An
e
24)
8.7
8
5
4
1
8
–14.5)
1.6
–187)
111)
44)
205)
5.3
1.6
3
6
6
6
2–91.2
9
9
7
4
24.0
7
0
11.3
19
11
3
2
1
1
5
2
7
2
5
7
telets i
olidined
weeksr; CABG  coronary artery bypass graft; GFR  glomerular filtration
nsity lipoprotein; PCI  percutaneous coronary intervention.
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Prognosis of Symptoms in Diabetes With CAD February 19, 2013:702–11estimated with the Kaplan-Meier method, and rate curves
were compared using the log-rank test. Multivariable Cox
regression models were built to estimate hazard ratios
(HRs). After adjustment for randomized strategies and
prespecified revascularization strata (PCI or CABG), the
stepwise selection algorithm chose significant confounders
from the baseline characteristics, including demographics,
clinical history, blood and urine measures, physical status,
5-Year Cumulative Rates of Outcomes and Hazard RatiosTable 2 5-Year Cumulative Rates of Outcomes and Hazard Rat
Outcome
None
(n  424)
Equivalent
(n  506)
All-cause death
Rates, % (n)* 10 (51) 14 (78)
Unadjusted HR 1.00 1.32 (0.83–2.09)
Adjusted HR† 1.00 1.17 (0.81–1.68)
Death/MI/stroke
Rates, % (n) 21 (90) 24 (121)
Unadjusted HR 1.00 1.12 (0.78–1.61)
Adjusted HR 1.00 1.11 (0.84–1.48)
CVD death
Rates, % (n) 5 (22) 8 (36)
Unadjusted HR 1.00 1.39 (0.69–2.80)
Adjusted HR 1.00 1.17 (0.67–1.57)
Nonfatal MI
Rates, % (n) 11 (46) 11 (53)
Unadjusted HR 1.00 0.98 (0.59–1.65)
Adjusted HR 1.00 1.04 (0.69–1.57)
Nonfatal stroke
Rates, % (n) 3 (10) 2 (11)
Unadjusted HR 1.00 0.94 (0.30–2.88)
Adjusted HR 1.00 0.86 (0.36–2.02)
Patien
None
(n  235)
Equivalent
(n  254)
All-cause death
Rates, % (n) 12 (31) 15 (42)
Unadjusted HR 1.00 1.29 (0.70–2.36)
Adjusted HR† 1.00 1.27 (0.68–2.38)
Death/MI/stroke
Rates, % (n) 23 (54) 27 (66)
Unadjusted HR 1.00 1.12 (0.70–1.80)
Adjusted HR 1.00 1.22 (0.74–2.00)
CVD death
Rates, % (n) 6 (14) 6 (14)
Unadjusted HR 1.00 0.94 (0.35–2.48)
Adjusted HR 1.00 0.81 (0.29–2.29)
Nonfatal MI
Rates, % (n) 12 (28) 15 (33)
Unadjusted HR 1.00 1.13 (0.57–2.16)
Adjusted HR 1.00 1.44 (0.71–2.90)
Nonfatal stroke
Rates, % (n) 3 (6) 2 (5)
Unadjusted HR 1.00 0.76 (0.16–3.63)
Adjusted HR 1.00 0.57 (0.12–2.78)angiographic characteristics, and relevant medications, aslisted in Table 1 and Online Table 1. The interaction effect
between baseline angina and randomized treatment strate-
gies was tested and dropped when there was no significant
interaction effect. For correction of the multiple comparison
issue, the statistical significance level was set at 0.01 by
Bonferroni correction. Analyses were performed using SAS
version 9.2 (SAS Institute Inc., Cary, North Carolina), and
plots were drawn using R (R Development Core Team,
All Patients
Angina
(n  1,434)
CCS I and II
(n  1,005)
CCS III and IV
(n  429)
12 (187) 11 (124) 12 (63)
1.14 (0.76–1.71) 1.08 (0.70–1.66) 1.27 (0.78–2.07)
1.11 (0.81–1.53) 1.10 (0.79–1.54) 1.14 (0.77–1.69)
24 (337) 23 (225) 26 (112)
1.15 (0.85–1.57) 1.09 (0.79–1.50) 1.30 (0.91–1.88)
1.17 (0.92–1.50) 1.14 (0.88–1.47) 1.26 (0.93–1.69)
6 (91) 6 (59) 7 (32)
1.26 (0.68–2.32) 1.17 (0.61–2.22) 1.47 (0.72–3.01)
1.20 (0.74–1.96) 1.18 (0.71–1.96) 1.25 (0.70–2.22)
14 (179) 14 (121) 15 (58)
1.21 (0.79–1.85) 1.15 (0.74–1.80) 1.33 (0.80–2.21)
1.22 (0.86–1.72) 1.20 (0.84–1.72) 1.26 (0.83–1.91)
3 (46) 3 (27) 5 (19)
1.42 (0.58–3.49) 1.18 (0.45–3.06) 2.02 (0.74–5.52)
1.10 (0.54–2.21) 0.92 (0.44–1.92) 1.54 (0.70–3.38)
domized to Optimal Medical Therapy
Angina
(n  702)
CCS I and II
(n  526)
CCS III and IV
(n  176)
11 (88) 16 (65) 10 (23)
0.98 (0.57–1.68) 0.98 (0.56–1.71) 0.98 (0.48–2.00)
1.07 (0.61–1.86) 1.08 (0.60–1.93) 1.03 (0.49–2.19)
24 (163) 25 (121) 22 (42)
1.02 (0.68–1.53) 1.03 (0.67–1.56) 1.01 (0.59–1.72)
1.17 (0.76–1.80) 1.21 (0.77–1.89) 1.04 (0.58–1.85)
7 (45) 7 (33) 7 (12)
1.10 (0.50–2.41) 1.09 (0.48–2.47) 1.14 (0.41–3.14)
1.20 (0.52–2.77) 1.21 (0.51–2.87) 1.18 (0.40–3.50)
15 (90) 16 (70) 13 (20)
1.10 (0.63–1.92) 1.15 (0.65–2.05) 0.95 (0.45–2.02)
1.32 (0.72–2.40) 1.42 (0.77–2.63) 1.02 (0.46–2.28)
3 (24) 3 (16) 5 (8)
1.37 (0.42–4.43) 1.22 (0.36–4.18) 1.82 (0.45–7.30)
0.89 (0.26–3.05) 0.78 (0.21–2.83) 1.23 (0.29–5.18)
Continued on the next pageios
ts RanWien, Austria).
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February 19, 2013:702–11 Prognosis of Symptoms in Diabetes With CADResults
Population baseline characteristics. Among the 2,364
patients at entry into the study, there were 1,434 (61%) with
angina, 506 (21%) with angina equivalents, and 424 (18%)
with neither angina nor angina equivalents. Among the
1,434 patients with angina, 1,005 had CCS grades I and II
and 429 had CCS grades III and IV. Baseline characteristics
by angina status are summarized in Table 1. The significant
results from the pairwise comparisons are presented for each
with p 0.01. Compared with patients in the other groups,
patients with angina were younger, were more often women,
and were more frequently on beta-blockers and nitrates.
Patients with angina had more previous PCIs than asymp-
tomatic patients and a slightly higher left ventricular ejec-
tion fraction compared with patients with equivalent an-
gina. Compared with the other groups, the asymptomatic
group had a higher rate of men and a lower rate of
hypertension; the asymptomatic patients had a higher index
of myocardium at risk compared with patients with equiv-
alent angina. Patients with equivalent angina were more
frequently on diuretics compared with the others. Body
mass index (BMI) differed among the 3 groups. There was
no significant difference among the 3 groups with respect to
the duration of diabetes, neuropathy score, lipid and glucose
profiles, blood pressure, smoking status, renal function,
previous MI, stroke, or use of aspirin, statins, and renin-
ContinuedTable 2 Continued
Patients Ra
Outcome
None
(n  189)
Equivalent
(n  252)
All-cause death
Rates, % (n) 8 (20) 13 (36)
Unadjusted HR 1.00 1.39 (0.68–2.85)
Adjusted HR† 1.00 1.11 (0.53–2.32)
Death/MI/stroke
Rates, % (n) 19 (36) 22 (55)
Unadjusted HR 1.00 1.14 (0.65–1.98)
Adjusted HR 1.00 1.08 (0.61–1.92)
CVD death
Rates, % (n) 4 (8) 9 (22)
Unadjusted HR 1.00 2.10 (0.73–6.09)
Adjusted HR 1.00 1.56 (0.53–4.65)
Nonfatal MI
Rates, % (n) 10 (18) 8 (20)
Unadjusted HR 1.00 0.85 (0.37–1.97)
Adjusted HR 1.00 0.82 (0.34–1.95)
Nonfatal stroke
Rates, % (n) 2 (4) 3 (6)
Unadjusted HR 1.00 1.17 (0.22–6.15)
Adjusted HR 1.00 1.24 (0.23–6.55)
*5-year cumulative event number. The CCS grades are subgroups of the angina group. No differe
computed from 2 models using no symptoms as the reference group. 1) baseline angina status
symptoms, equivalent, CCS I and II, and CCS III and IV. There was no significant difference in eac
CCS  Canadian Cardiovascular Society; CVD  cardiovascular disease; HR  hazard ratio; MIangiotensin modulators. 6Treatment of patients during the follow-up. Compared
with the baseline observations, each of the 3 groups at the
3-year follow-up had a decrease in the rates of current
smokers, HbA1c, low-density lipoprotein cholesterol, and
lood pressure and an increase in high-density lipopro-
ein cholesterol. However, there was a small but signifi-
ant increase in BMI in the 3 groups. Use of long-acting
itrates decreased, and use of beta-blockers and calcium
hannel blockers increased; there was significantly higher
se of nitrates and calcium blockers in the angina group.
uring the 3-year follow-up, the asymptomatic patients
ad a lower rate of subsequent PCI than the patients in
he other 2 groups, but there was no difference in the
ates of subsequent CABG among the 3 groups (Online
able 2). At the 5-year follow-up, the cumulative
aplan-Meier rates of the subsequent revascularization
PCI or CABG) were 25% (98 of 424) in the asymptom-
tic group, 32% (144 of 506) in the equivalent angina
roup, and 35% (450 of 1,434) in the angina group (p 
.001). The 4 main independent reasons for revascular-
zation in the asymptomatic group at entry were acute
oronary syndrome in 28.6%, worsened ischemia in
2.4%, severe angina in 22.4%, and CAD progression in
2%. For the angina equivalent and angina groups, it was
evere angina in 45% for both groups, acute coronary
yndrome in 22.2% and 23.3%, worsened ischemia in
4.6% and 17.8%, and CAD progression in 11.8% and
ized to Prompt Revascularization Therapy
Angina
(n  732)
CCS I and II
(n  479)
CCS III and IV
(n  253)
12 (99) 11 (59) 13 (40)
1.36 (0.72–2.56) 1.23 (0.63–2.40) 1.61 (0.80–3.26)
1.27 (0.66–2.46) 1.21 (0.61–2.40) 1.41 (0.66–3.00)
24 (174) 22 (104) 28 (70)
1.34 (0.84–2.15) 1.20 (0.73–1.97) 1.64 (0.97–2.78)
1.29 (0.79–2.13) 1.17 (0.70–1.97) 1.58 (0.90–2.78)
6 (46) 5 (26) 8 (20)
1.54 (0.58–4.14) 1.33 (0.47–3.77) 1.95 (0.67–5.74)
1.33 (0.48–3.70) 1.22 (0.42–3.57) 1.54 (0.50–4.75)
13 (89) 12 (51) 16 (38)
1.37 (0.71–2.68) 1.18 (0.58–2.40) 1.76 (0.84–3.68)
1.27 (0.63–2.57) 1.13 (0.54–2.36) 1.59 (0.72–3.51)
3 (22) 2 (11) 6 (11)
1.52 (0.37–6.16) 1.13 (0.25–5.11) 2.29 (0.51–10.33)
1.35 (0.32–5.61) 1.03 (0.23–4.73) 2.04 (0.43–9.54)
the event rates among the 3 groups or the subgroups. †HR with 99% CI for each outcome was
ategories: no symptoms, equivalent, and angina. 2) baseline angina status as 4 categories: no
outcomes between the groups.
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and 548 patients with a first occurrence of the composite of
all-cause death, nonfatal MI, or nonfatal stroke. The cumu-
lative 5-year death rate was 12% in patients with angina,
14% in patients with angina equivalents, and 10% in
asymptomatic patients (log-rank p  0.3). The cumulative
5-year composite outcome rate was 24% in patients with
angina, 24% in patients with angina equivalents, and 21% in
asymptomatic patients (Fig. 1). As shown in Table 2, there
was no difference in the unadjusted HR as well as the HR
adjusted for all covariates between the asymptomatic group
and each of the symptomatic groups for all-cause mortality,
composite outcome, cardiovascular disease (CVD) death, non-
fatal MI, and nonfatal stroke.
Stratified analyses were performed on patients random-
ized to the prompt revascularization strategy as well as
patients randomized to the optimal medical strategy to
address the possible confounding effect of the initial revas-
cularization procedures. In the patients randomized to
optimal medical group strategy, there were no significant
Figure 1 Kaplan-Meier Event Rates According to Symptom Sta
The events are the first occurrence of the composite outcome (all-cause death, no
stroke is nonfatal stroke. None represents patients with neither angina nor angina
according to log-rank test. K-M  Kaplan-Meier.differences among the asymptomatic, angina equivalent, and dangina groups for the cumulative 5-year death rate, death,
MI or stroke, CVD death, nonfatal MI, and nonfatal stroke;
there was also no difference in the unadjusted and adjusted
HR between the 3 groups and the different outcomes
(Table 2, Online Fig. 1). Similar findings were observed for
the same outcomes in the 3 groups of patients randomized
to the prompt revascularization strategy (Table 2, Online
ig. 2).
There was also no difference in the adjusted HR for each
utcome between the asymptomatic group and the symp-
omatic groups when the data were restricted to the 842
atients with either triple-vessel disease or double-vessel
isease including left proximal anterior descending coronary
rtery stenosis (Online Table 3).
The higher rates of outcomes among patients with CCS
rades III and IV compared with patients with CCS grades
and II were not statistically different and not different
hen compared with asymptomatic patients and patients
ith angina equivalents (Table 2). However, patients with
CS grades III and IV had higher rates of revascularization
t Entry
myocardial infarction [MI], or nonfatal stroke), death; MI is nonfatal MI, and
alent (Equiv.). There were no differences among the 3 groups for each eventtus a
nfatal
equivuring the study (Fig. 2).
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In this study, patients with stable CAD and type 2 diabetes
had a similar long-term prognosis across a variety of
cardiovascular outcomes irrespective of their symptom
status. Indeed, asymptomatic patients at entry into the
study were at the same relatively high risk for all-cause
mortality, the composite outcome, CVD death, nonfatal
MI, and nonfatal stroke as patients with angina and
patients with angina equivalent symptoms. These obser-
vations were independent of clinical baseline character-
istics, severity of CAD, and coronary revascularization.
Furthermore, the results remained unchanged when the
optimal medical therapy arm and the revascularization
arm were analyzed separately.
A recent analysis of the symptoms at entry into the BARI
2D patients showed that the absence of angina in the
asymptomatic or angina equivalent patients may be ex-
plained in part by a previous revascularization (8), but nearly
half of them presented with angina during the follow-up
Figure 2 Kaplan-Meier Rates of First Coronary Revascularizatio
Participants randomized to the optimal medical strategy (MED) with Canadian Card
compared with participants with CCS angina grades I and II. For participants rando
grade IV had a higher rate of revascularization compared with the 3 other groups.(9). Nevertheless, it remains intriguing why patients withoutangina but with documented myocardial ischemia had no
symptoms or an angina equivalent. A study using positron
emission tomography to evaluate regional cerebral blood
flow suggested that abnormal central nervous system pro-
cessing of painful stimuli is associated with silent myocardial
ischemia (10). Autonomic neuropathy has also been
thought to explain the lower frequency of angina in patients
with diabetes and evidence of myocardial ischemia com-
pared with patients without diabetes (11–14). Regardless of
the mechanisms responsible for symptom status in patients
with diabetes and CAD, our findings suggest that these very
different presentations are not explained by differences in
the angiographic severity of CAD nor in left ventricular
function.
Patients with and without diabetes and silent myocardial
ischemia have better survival than patients with symptom-
atic ischemia 6 months after PCI (3). However, similar
survival rates were reported between 45 asymptomatic and
37 angina patients with diabetes, documented angiographic
cording to CCS Angina Grades
ular Society (CCS) angina grades III and IV had a higher rate of revascularization
to the prompt revascularization strategy (REV), only those with CCS angina
Kaplan-Meier.n Ac
iovasc
mized
K-M CAD, and myocardial ischemia during a 6-year follow-up
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were found in 286 asymptomatic and 321 angina patients
with diabetes and induced myocardial ischemia but without
documented CAD during a median follow-up of 2 years (2).
Our results confirmed these 2 studies in a much larger
population followed for 5.3 years and included more out-
comes and showed no difference in survival of patients
according to their symptoms even after coronary revas-
cularization. Considering the whole spectrum of silent
ischemia in patients with type 2 diabetes, these findings
are consistent with the similar survival rates between
patients with diabetes with unrecognized MI and those
with recognized MI (15).
It might have been expected that the predominance of
exertion dyspnea as an angina equivalent would be
associated with poorer left ventricular function and out-
comes, as reported by Zellweger et al. (2), but this was
not the case in our study in which left ventricular ejection
fractions were 55%, 58%, and 57% in patients with
angina equivalent symptoms, angina, and no symptoms,
respectively. However, it is possible that exertion dyspnea
may be related to diastolic ventricular dysfunction during
exercise-induced ischemia, a variable not assessed in most
of the patients. We cannot exclude the possibility that
exertion dyspnea might have been related to other non-
cardiac factors such as increased BMI and physical
deconditioning. It is interesting to note that myocardial
jeopardy score was actually significantly highest in the
asymptomatic subset and not in the angina equivalent
subset. In contrast to the findings of Zellweger et al. (2),
we found no significant difference in the outcomes
between the patients who had only dyspnea compared
with the others who did not (Online Table 4).
Recruitment in the BARI 2D study was completed
among patients with stable CAD and myocardial ischemia
with mainly mild or no symptoms. However, a third of the
patients with angina were classified as CCS grades III and
IV, and half of the latter had a stable status before
randomization after a recent history of unstable angina.
These patients did not have significantly higher rates of
events compared with patients with CCS grades I and II, as
previously reported in a cohort of consecutive patients
undergoing coronary angiographic studies (16). However,
participants with CCS grades III and IV angina did have a
higher rate of revascularization during the study than those
with angina grades I and II. Although this may be one of
the factors explaining the nonsignificant differences, the
CCS gradation is known to have limitations, particularly for
CCS grade IV (17).
Study limitations. Our study was a post-hoc analysis of the
BARI 2D trial with its inherent limitations and should be
considered as a hypothesis-generating study. The BARI 2D
cohort was a selected population with stable CAD anatomy
suitable for revascularization without standardized testing to
determine the myocardial ischemia threshold. Nevertheless,
our study has several strengths: it is based on a large sampleof patients with well-documented and detailed baseline
characteristics including systematic coronary angiography,
myocardial ischemia, intensive risk factor management dur-
ing a long follow-up, close monitoring, and blinded adju-
dication of fatal and nonfatal outcomes. Our findings have
clinical relevance considering that these relatively high-risk
patients with different stable symptomatology have similar
cardiovascular prognosis.
Conclusions
Asymptomatic patients with type 2 diabetes, stable CAD,
and documented myocardial ischemia are at high risk for
all-cause mortality and major cardiovascular outcomes,
and their risk is similar to the risk of patients with angina
and angina equivalent symptoms. Our findings suggest
that all of these patients should be similarly managed in
terms of risk stratification and preventive therapies.
Reprint requests and correspondence: Dr. Gilles R. Dagenais,
Institut Universitaire de Cardiologie et de Pneumologie de Qué-
bec, 2725 Chemin Ste-Foy, Québec, Quebec City G1V 4G5,
Canada. E-mail: gilles.dagenais@criucpq.ulaval.ca.
REFERENCES
1. Weiner DA, Ryan TJ, Parsons L, et al. Significance of silent
myocardial ischemia during exercise testing in patients with diabetes
mellitus: a report from the Coronary Artery Surgery Study (CASS)
registry. Am J Cardiol 1991;68:729–34.
2. Zellweger MJ, Hachamovitch R, Kang X, et al. Prognostic relevance of
symptoms versus evidence of coronary artery disease in diabetic
patients. Eur Heart J 2004;25:543–50.
3. Zellweger MJ, Weinbacher M, Zutter AW, et al. Long-term outcome
of patients with silent versus symptomatic ischemia six months after
percutaneous coronary intervention and stenting. J Am Coll Cardiol
2003;42:33–40.
4. The BARI 2D Study Group. A randomized trial of therapies for type
2 diabetes and coronary artery disease. N Engl J Med 2009;360:
2503–15.
5. Brooks MM, Frye RL, Genuth S, et al. Hypotheses, design, and
methods for the Bypass Angioplasty Revascularization Investigation 2
Diabetes (BARI 2D) trial. Am J Cardiol 2006;97b Suppl:9G–19G.
6. The BARI 2D Study Group. Baseline characteristics of patients with
diabetes and coronary artery disease enrolled in the Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am
Heart J 2008;156:528–36.
7. Campeau L. Grading of angina pectoris. Circulation 1976;54:522–3.
8. Krishnaswami A, Hardison R, Nesto RW, Sobel B. Presentation in
patients with angiographically documented coronary artery disease and
type II diabetes mellitus (from BARI 2D clinical trial) Am J Cardiol
2012;109:36–41.
9. Dagenais GR, Lu J, Faxon DP, et al. Effects of optimal medical
treatment with or without coronary revascularization on angina and
subsequent revascularization in patients with type 2 diabetes mellitus
and stable ischemic heart disease. Circulation 2011;123:1492–500.
10. Rosen SD, Paulesu E, Nihoyannopoulos P, et al. Silent ischemia as a
central problem: regional brain activation compared in silent and
painful ischemia. Ann Intern Med 1996;124:939–49.
11. Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional
myocardial ischemia in diabetic and nondiabetic patients: assess-
ment by exercise thallium scintigraphy. Ann Intern Med 1988;
108:170 –5.
12. Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW.
Detection of silent ischemia in diabetes mellitus. Am J Cardiol
1991;67:1073–8.
711JACC Vol. 61, No. 7, 2013 Dagenais et al.
February 19, 2013:702–11 Prognosis of Symptoms in Diabetes With CAD13. Yamasaki Y, Nakajima K, Kusuoka H, et al. Prognostic value of gated
myocardial perfusion imaging for asymptomatic patients with type 2
diabetes. Diabetes Care 2010;33:2320–6.
14. Conti CR, Bavry AA, Petersen JW. Silent ischemia. Clinical rele-
vance. J Am Coll Cardiol 2012;59:435–41.
15. Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silent
myocardial infarction in type 2 diabetes and the effect of fenofibrate: an
analysis from the Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study. Eur Heart J 2010;31:92–9.
16. Hemingway H, Fitzpatrick NK, Gnani S, et al. Prospective validity of17. Kaul P, Naylor D, Armstrong PW, et al. Assessment of activity status
and survival according to the Canadian Cardiovascular Society angina
classification. Can J Cardiol 2008;25:e225–31.
Key Words: angina y coronary artery disease y silent ischemia y type 2
diabetes.
APPENDIX
For supplementary tables and figures,measuring angina severity with Canadian Cardiovascular Society class:
the ACRE study. Can J Cardiol 2004;20:305–9. please see the online version of this article.
Go to http://cme.jaccjournals.org
to take the CME quiz for this article.
